|
| Study | Design, sample size and study duration | NSAID | Treatment group(s) | Outcomes | Author conclusions |
|
Boyer et al.
(2007) [55] | Randomized, prospective, placebo-controlled
57 eyes
3 months | Diclofenac 0.1% | Diclofenac with PDT (C) versus PDT for subfoveal classic CNV | No improvement in VA, lesion area, GLD, fluorescein leakage, or CMT | No added benefit of diclofenac to PDT for subfoveal classic CNV |
|
Grant
(2008) [56] | Retrospective, comparative
60 eyes
6 months | Bromfenac 0.09% | Bromfenac with IVR (C) versus IVR for wet AMD | VA increased more in C group ()
Fewer injections in C group () | Combination therapy with bromfenac may be more efficacious than IVR alone |
|
Zweifel et al.
(2009) [53] | Retrospective, uncontrolled
22 eyes
2 months | Bromfenac 0.09% | Bromfenac with IVR/IVB for persistent SRF/IRF | VA and CMT unchanged at end of study | No added benefit of bromfenac to standard of care |
|
Chen et al.
(2010) [54] | Retrospective, uncontrolled
25 eyes
3 months | Nepafenac 0.1% | Nepafenac with IVR/IVB for persistent SRF/IRF/PED | VA and CMT unchanged at end of study | No significant change in VA or OCT with the addition of nepafenac |
|
Flaxel et al.
(2012) [57] | Randomized, prospective, controlled,
30 eyes
12 months | Bromfenac 0.09% | Bromfenac with IVR (C) versus IVR for new/recurrent exudative AMD | No difference for VA and no. of injections, but
CMT decreased more in C group () | Combination therapy with bromfenac may be more efficacious than IVR alone |
|
Gomi et al.
(2012) [58] | Randomized, prospective, placebo-controlled,
38 eyes
6 months | Bromfenac 0.1% | Bromfenac with IVR (C) versus IVR for exudative AMD | Fewer injections in C group ()
VA similar ()
CMT tended to be lower in C group () | Bromfenac may reduce the need for intravitreal injections |
|
